Two-Year CATT Study of Results for Avastin vs. Lucentis in Treating Wet AMD
May 2, 2012
Submit Comments
The NEI and the CATT Study Group have just released the two-year results of the CATT Study, comparing Avastin and Lucentis for the treatment of wet AMD. Basically, after two years, there is no significant difference either between the two drugs or the dosing methods studied – once monthly or as needed.
There were slightly more adverse events in those patients using Avastin than Lucentis, but the study’s authors concluded that the differences were not specifically associated with the use of Avastin, but more likely due to the age of the subjects in the study – a median age of 80 years.
For more details, please see the complete writeup at the following link.
Comments (0)
Trackbacks
Print this post
Filed in Clinical Trials, Industry News, Macular Degeneration, Research
You might also enjoy...
- Which is More Effective – Avastin or Lucentis?
- CATT Study Finds No Difference Between Avastin and Lucentis in Stopping Progression of Wet Macular Degeneration
- Quick Updates from ARVO 2011
- Avastin vs. Lucentis: The Origin of the Debate
- Should Avastin Become the Standard of Care for Wet AMD?
Comments
Jump down to form below to submit your own comments
